Factors associated with mortality in hospitalized cardiovascular disease patients infected with COVID‐19

Introduction To reduce mortality in hospitalized patients with COVID‐19 and cardiovascular disease (CVD), it is necessary to understand the relationship between patient's symptoms, risk factors, and comorbidities with their mortality rate. To the best of our knowledge, this paper is the first w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunity, Inflammation and Disease Inflammation and Disease, 2022-03, Vol.10 (3), p.e561-n/a
Hauptverfasser: Alizadehsani, Roohallah, Eskandarian, Rahimeh, Behjati, Mohaddeseh, Zahmatkesh, Mehrdad, Roshanzamir, Mohamad, Izadi, Navid H., Shoeibi, Afshin, Haddadi, Azadeh, Khozeimeh, Fahime, Sani, Fariba A., Sani, Zahra A., Roshanzamir, Zahra, Khosravi, Abbas, Nahavandi, Saeid, Sarrafzadegan, Nizal, Islam, Sheikh Mohammed Shariful
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction To reduce mortality in hospitalized patients with COVID‐19 and cardiovascular disease (CVD), it is necessary to understand the relationship between patient's symptoms, risk factors, and comorbidities with their mortality rate. To the best of our knowledge, this paper is the first which take into account the determinants like risk factors, symptoms, and comorbidities leading to mortality in CVD patients who are hospitalized with COVID‐19. Methods This study was conducted on 660 hospitalized patients with CVD and COVID‐19 recruited between January 2020 and January 2021 in Iran. All patients were diagnosed with the previous history of CVD like angina, myocardial infarction, heart failure, cardiomyopathy, abnormal heart rhythms, and congenital heart disease before they were hospitalized for COVID‐19. We collected data on patient's signs and symptoms, clinical and paraclinical examinations, and any underlying comorbidities. t test was used to determine the significant difference between the two deceased and alive groups. In addition, the relation between pairs of symptoms and pairs of comorbidities has been determined via correlation computation. Results Our findings suggest that signs and symptoms such as fever, cough, myalgia, chest pain, chills, abdominal pain, nausea, vomiting, diarrhea, and anorexia had no impact on patients' mortality. There was a significant correlation between COVID‐19 cardiovascular patients' mortality rate and symptoms such as headache, loss of consciousness (LOC), oxygen saturation less than 93%, and need for mechanical ventilation. Conclusions Our results might help physicians identify early symptoms, comorbidities, and risk factors related to mortality in CVD patients hospitalized for COVID‐19. Our findings suggest that signs and symptoms such as fever, cough, myalgia, chest pain, chills, abdominal pain, nausea, vomiting, diarrhea, and anorexia had no impact on patients` mortality. There was a significant correlation between COVID‐19 cardiovascular patients' mortality rate and symptoms such as headache, loss of consciousness (LOC), oxygen saturation less than 93%, and need for mechanical ventilation. Our results might help physicians identify early symptoms, comorbidities, and risk factors related to mortality in cardiovascular disease patients hospitalized for COVID‐19.
ISSN:2050-4527
2050-4527
DOI:10.1002/iid3.561